Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
While this supports patient access, compounded therapies threaten the clinical value story of FDA-approved weight-loss therapies
This vaccine is being manufactured at the Duke Human Vaccine Institute for Phase-I testing in humans
Baliga MS, Wang H, Zhuo P, Schwartz JL, Diamond AM
The diagnosis of MPNST remains a challenge, given its clinical behavior similar to that of other sarcomas
Saroglitazar, a PPAR-/ agonist, at a dosage of 4 mg qd significantly improved ALT, liver fat content (LFC), insulin resistance, and atherogenic dyslipidemia in patients with MASLD/MASH (NCT03061721)
US$ 20.93
US$ 29.72
US$ 20.09
US$ 20.39
US$ 25.65
